CA
NZ
UK
AU
IND
US
$1.25 Million Promissory Note Restructured
Chemed Corp (NYSE: CHE) recorded strong second-quarter results, highlighted by a remarkable 43.7% rise in GAAP diluted earnings per share (EPS) to $5.13. The company also announced an adjusted diluted EPS of $6.06, surpassing the consensus estimate of $5.66, solidifying its position in the …
InfuSystem Holdings, Inc. (NYSE American: INFU) is set to release its financial results for the second quarter of 2026 in early August. The reported earnings per share for the prior quarter already exceeded market expectations, suggesting the company’s capacity to navigate a competitive healthcare …
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) reported earnings per share of $0.30 for the recent quarter, exactly aligning with analyst consensus. The result reaffirmed the firm’s financial discipline and set a steady foundation for its ongoing development programs. With earnings on target, the market’s …
Relmada Therapeutics (NASDAQ: RLMD) is invigorating its executive team by appointing Bipin Dalmia as Chief Business Officer. Dalmia's extensive background in non-muscle invasive bladder cancer (NMIBC) and corporate strategy comes at a critical juncture for the company. His leadership is anticipated to significantly influence …
The anticipated changes to Medicare's drug pricing program are set to have repercussions that may affect the financial environment for healthcare companies, including COLRF. As the government moves forward with alterations aimed at addressing drug affordability, experts predict that more seniors may be tempted …
Alkermes plc reported earnings per share of $0.00, exceeding a consensus estimate of $-0.02. Despite a strong year-to-date growth of 78.1% in share value, the stock fell 4.53% following the quarterly update, illustrating investor caution amidst ongoing market fluctuations and insider activity.Key HighlightsAlkermes reported …
Bicara Therapeutics Inc. This transition in leadership is important for the company as it seeks to enhance its focus on commercialization strategies, particularly as it advances its lead candidate, ficerafusp alfa, a bifunctional therapy targeting solid tumors. This board shift marks a significant moment …
Boston Scientific Corporation (BSX) has launched a comprehensive restructuring plan estimated to generate annual pre-tax savings of approximately $500 million. While the initiative will involve job cuts, the company aims to create new positions in growth areas, presenting a mixed outlook for investors amid …
Incyte Corporation achieved second-quarter earnings of $3.09 per share, surpassing consensus expectations of $2.14, amid a 38% revenue increase to $1.67 billion. This strong performance, driven by core product growth, positions the company favorably ahead of several upcoming clinical data releases.Key HighlightsIncyte reported Q2 …
Please wait processing your request...